Payer cost savings with endometrial ablation therapy

R London, Ruth London, M Holzman, Michael D. Holzman, David A. Rubin, D Rubin, B Moffitt
The American journal of managed care · 1999 · vol. 5(7) , pp. 889–97 · PMID:10557409 · W80106721
Observational OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Endometrial ablation therapy for dysfunctional uterine bleeding, when used instead of hysterectomy, offers payers an average per-case savings of $4,300 and substantial annual savings for larger plans.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

CONTEXT: Dysfunctional uterine bleeding (DUB) is a significant cost burden for payers in the US healthcare system because hysterectomy, the common curative treatment, is associated with high hospitalization costs. OBJECTIVE: To determine the potential economic benefit to payers of endometrial ablation as an alternate treatment for the benign DUB disorder. STUDY DESIGN: A retrospective analysis of healthcare claims including the total direct costs to the payer (reimbursement) and patient (copayment). The study was designed to capture all DUB-related claims costs for the entire episode of care from initial diagnosis through follow-up care for 12 months postprocedure. PATIENTS AND METHODS: Twenty-four months of claims data from premenopausal women aged 25 to 50 years enrolled in a large managed care organization were screened based on relevant diagnostic and procedural codes. Incidence and costs of hysterectomy and ablation were determined, and potential payer savings were calculated based on hypothetical hysterectomy-to-ablation conversion rates of 25% to 50%. RESULTS: By performing ablation in lieu of hysterectomy for DUB, an average per-case savings of approximately $4,300 is possible. Potential annual payer savings are approximately $515,000 and $1.03 million for a 1-million-member plan, based on the 25% and 50% conversion rates, respectively. The recently approved uterine balloon therapy ablation technique could be instrumental in overcoming current barriers to wider utilization of ablation surgery. CONCLUSION: If ablation is used in lieu of hysterectomy when medically appropriate, a payer organization could reduce the cost of treating patients with DUB who are not responsive to drug therapy or dilation and curettage alone. Our data suggest that hysterectomy is the most common surgical therapy for this disorder, even though the less invasive endometrial ablation approach is more consistent with accepted DUB treatment guidelines. Payers therefore have an economic incentive to adopt guidelines and reimbursement policies that promote ablation therapy for DUB.

My notes (saved in your browser only)

MeSH descriptors

Catheterization Gynecologic Surgical Procedures Health Care Costs Hysterectomy Managed Care Programs Uterine Hemorrhage Adult Catheterization Catheterization Cost Savings Cost Savings Direct Service Costs Direct Service Costs Endometrium Female Gynecologic Surgical Procedures Health Care Costs Humans Hysterectomy Hysterectomy

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (18)

Source provenance

openalex
last seen: 2026-05-14T07:21:23.935093+00:00
pubmed
last seen: 2026-10-08T20:59:07.345995+00:00
License: CC0 · commercial use OK